GSDMB: A Protein Involved in Signaling and Drug Response (G55876)

Target Name: GSDMB

NCBI ID: G55876

GSDMB

GSDMB: A Protein Involved in Signaling and Drug Response

GSDMB, or Gasdermin B, is a protein that is expressed in various tissues throughout the body, including the brain, heart, kidneys, and liver. It is a member of the G-protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a critical role in cellular signaling.

GSDMB is characterized by its unique transmembrane structure, which consists of a catalytic region, a transmembrane region, and an intramembrane region. The catalytic region contains a catalytic active site that is optimized for the binding of small molecules, such as drugs or other signaling molecules. The transmembrane region is responsible for the protein's ability to interact with the intramembrane region, and the intramembrane region is responsible for the protein's ability to interact with other proteins.

GSDMB is involved in a wide range of physiological processes in the body, including drug response, metabolism, and signaling. For example, GSDMB is involved in the regulation of neurotransmitter release from neurons, which is critical for the function of the brain. It is also involved in the regulation of glucose metabolism, which is critical for maintaining energy homeostasis.

GSDMB has also been shown to be a potential drug target in several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. For example, GSDMB has been shown to promote the growth of cancer cells, which is a potential mechanism for the development of cancer. It has also been shown to contribute to the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In addition to its potential as a drug target, GSDMB is also a valuable biomarker for several diseases. For example, GSDMB has been shown to be elevated in the brains of individuals with Alzheimer's disease, which suggests that it may be a promising biomarker for this disease. It has also been shown to be elevated in the blood of individuals with Parkinson's disease, which suggests that it may be a promising biomarker for this disease as well.

GSDMB is also a potential target for drug development in other diseases, including cardiovascular diseases and neurodegenerative diseases. For example, GSDMB has been shown to be involved in the regulation of blood pressure, which is a critical factor in the development of cardiovascular diseases. It is also involved in the regulation of muscle contractions, which is a critical factor in the development of neurodegenerative diseases.

In conclusion, GSDMB is a protein that is expressed in various tissues throughout the body and is involved in a wide range of physiological processes in the body. It is a member of the GPCR family and has been shown to be involved in the regulation of drug response, metabolism, and signaling. In addition to its potential as a drug target, GSDMB is also a valuable biomarker for several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. As a result, GSDMB is a promising target for drug development in these diseases.

Protein Name: Gasdermin B

Functions: Precursor of a pore-forming protein that acts as a downstream mediator of granzyme-mediated cell death (PubMed:32299851). This form constitutes the precursor of the pore-forming protein: upon cleavage, the released N-terminal moiety (Gasdermin-B, N-terminal) binds to membranes and forms pores, triggering pyroptosis (PubMed:32299851). Also acts as a regulator of epithelial cell repair independently of programmed cell death: translocates to the plasma membrane and promotes epithelial maintenance and repair by regulating PTK2/FAK-mediated phosphorylation of PDGFA (PubMed:35021065)

The "GSDMB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GSDMB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets